Roche Holding AG Net Income/Loss 2010-2024 | RHHBY
Roche Holding AG annual/quarterly net income/loss history and growth rate from 2010 to 2024. Net income/loss can be defined as the company's total income or loss before preferred stock dividends, taken from the Income Statement
- Roche Holding AG net income/loss for the quarter ending December 31, 2024 was $10.436B, a 10% increase year-over-year.
- Roche Holding AG net income/loss for the twelve months ending December 31, 2024 was $46.793B, a 7.64% decline year-over-year.
- Roche Holding AG annual net income/loss for 2024 was $10.436B, a 24.19% decline from 2023.
- Roche Holding AG annual net income/loss for 2023 was $13.766B, a 2.92% decline from 2022.
- Roche Holding AG annual net income/loss for 2022 was $14.179B, a 13.23% decline from 2021.
Roche Holding AG Annual Net Income/Loss
(Millions of US $) |
| 2024 |
$10,436 |
| 2023 |
$13,766 |
| 2022 |
$14,179 |
| 2021 |
$16,340 |
| 2020 |
$16,072 |
| 2019 |
$14,200 |
| 2018 |
$11,108 |
| 2017 |
$8,969 |
| 2016 |
$21,550 |
| 2015 |
$21,492 |
| 2014 |
$22,220 |
| 2013 |
$22,449 |
| 2012 |
$21,325 |
| 2011 |
$10,807 |
| 2010 |
$0 |
| 2009 |
$17,829 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$253.013B |
$68.726B |
|
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
|
